| |
|
Product Name:
|
Vaccinia Virus, Western Reserve, Recombinant Expressing Whitewater Arroyo Virus, AV 9310135 Glycoprotein Precursor
|
|
Ownership statement:
|
This reagent is the property of the U.S. Government.
|
|
Manufacturer:
|
BEI Resources
|
|
Taxonomy:
|
Virus Classification: Poxviridae, Orthopoxvirus
Agent: Vaccinia virus
Strain: rVACV-WWAV GPC [Vaccinia virus (VACV), Western Reserve, recombinant expressing the glycoprotein precursor (GPC) of Whitewater Arroyo virus (WWAV), AV 9310135]
|
|
Additional Information:
|
WWAV is an Arenavirus (Arenaviridae, Mammarenavirus) which has been tentatively associated with hemorrhagic fever and acute respiratory distress syndrome, acute central nervous system disease, and undifferentiated febrile illness in humans in the United States.2,3,4
|
|
Material Provided:
|
Each vial contains approximately 1 mL of cell lysate and supernatant from Chlorocebus aethiops kidney epithelial cells (BSC-40, ATCC® CRL-2761™) infected with vaccinia virus, rVACV-WWAV GPC.
Note: If homogeneity is required for your intended use, please purify prior to initiating work.
|
|
Packing/Storage:
|
NR-15508 was packaged aseptically, in cryovials. The product is provided frozen on dry ice and should be stored at -60°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.
|
|
Growth Conditions:
|
Host: BSC-40 cells (ATCC® CRL-2761™)
Growth Medium: Dulbecco’s Modified Eagle Medium containing 4 mM L-glutamine, 4500 mg/L glucose, 1 mM sodium pyruvate and 1500 mg/L sodium bicarbonate supplemented with 10% fetal bovine serum.
Infection: Cells should be 80% to 100% confluent
Incubation: 2 to 4 days at 37°C and 5% CO2
Cytopathic Effect: Cell rounding and sloughing
|
|
Disclaimers:
|
You are authorized to use this product for research use only. It is not intended for human use. Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org. While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate. This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/ or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products. |
References:
|
1. Kotturi, M. F., et al. “A Multivalent and Cross-Protective Vaccine Strategy Against Arenaviruses Associated with Human Disease.” PLoS Pathog. 5 (2009): e1000695. PubMed: 20019801.
2. Fulhorst, C. F., et al. “Isolation and Characterization of Whitewater Arroyo Virus, a Novel North American Arenavirus.” Virology 224 (1996): 114-120. PubMed: 8862405.
3. Centers for Disease Control and Prevention. “Fatal Illnesses Associated with a New World Arenavirus – California, 1999-2000.” MMWR Morb. Mortal. Wkly. Rep. 49 (2000): 709-711. PubMed: 10958585.
4. Milazzo, M. L., G. L. Campbell and C. F. Fulhorst. “Novel Arenavirus Infection in Humans, United States.” Emerg. Infect. Dis. 17 (2011): 1417-1420. PubMed: 21801618.
|
|
Citation:
|
Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: Vaccinia Virus, Western Reserve, Recombinant Expressing Whitewater Arroyo Virus, AV 9310135 Glycoprotein Precursor, NR-15508."
|
|
Biosafety Level:
|
2
Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories (BMBL). Current Edition. Washington, DC: U.S. Government Printing Office.
|